AstraZeneca to Receive $400 Million From Takeda in Deal to Develop Parkinson’s Treatment

AstraZeneca (AZN) is set to receive as much as $400 million, including initial revenue this year, from Japan’s Takeda after the companies agreed to pool resources to develop MEDI1341 for Parkinson’s disease.

The companies will share equally future development and selling costs for MEDI1341, as well as any future revenues, AstraZeneca said on Tuesday. AstraZeneca will get further payments after this year that are tied to sales and development milestones.

MEDI1341 is an antibody to the alpha-synuclein protein which contributes to the development of Parkinson’s when it builds up in the nerve cells, according to AstraZeneca, which discovered the compound. These accumulated proteins then spread across the nervous system aggravating the condition, the drugmaker said.

“Today there are no medicines that can slow or halt the degenerative progress of Parkinson’s disease,” said Mene Pangalos, executive vice president for the innovative medicines unit at AstraZeneca. “By combining our scientific expertise and sharing the risks and cost of development, we hope to accelerate the advancement of MEDI1341 as a promising new approach.”

The deal with Takeda, which is a specialist in neuroscience, frees up resources for AstraZeneca, which is focusing on the development of cancer treatments and drugs for respiratory diseases, such as the recently approved Imfinzi for bladder cancer and Faslodex for breast cancer as well as Bevespi for chronic obstructive pulmonary disease, which is under review by regulators.

By Sparta Contributor